1,226
Views
45
CrossRef citations to date
0
Altmetric
Original Article

Occupational exposure limit for silver nanoparticles: considerations on the derivation of a general health-based value

, , , , , & show all
Pages 945-956 | Received 10 Nov 2015, Accepted 27 Jan 2016, Published online: 16 Mar 2016

References

  • ACGIH (American Conference of Governmental Industrial Hygienists). 2013. TLVs and BEIs. Cincinnati, OH: ACGIH.
  • Allen BC, Kavlock RJ, Kimmel CA, Faustman EM. 1994. Dose–response assessment for developmental toxicity. II. Comparison of generic benchmark dose estimates with no observed adverse effect levels. Fundam Appl Toxicol 23:487–95.
  • Aschberger K, Johnston HJ, Stone V, Aitken RJ, Hankin SM, Peters SA, et al. 2010. Review of carbon nanotubes toxicity and exposure-appraisal of human health risk assessment based on open literature. Crit Rev Toxicol 40:759–90.
  • Asgharian B, Price O, Miller F, Subramaniam R, Cassee FR, Freijer J, et al. 2009. Multiple-Path Particle Dosimetry Model (MPPD v2.11): A Model for Human and Rat Airway Particle Dosimetry. In Hamner Institutes for Health Sciences Applied Research Associates (ARA), National Institute for Public Health and the Environment (RIVM), and Ministry of Housing, Spatial Planning and the Environment, editor. Raleigh, NC: Applied Research Associates (ARA).
  • AshaRani PV, Low Kah Mun G, Hande MP, Valiyaveettil S. 2009. Cytotoxicity and genotoxicity of silver nanoparticles in human cells. ACS Nano 3:279–90.
  • Borm P, Cassee FR, Oberdorster G. 2015. Lung particle overload: old school -new insights? Part Fibre Toxicol 12:10.
  • Boudreau MD, Imam MS, Paredes AM, Bryant MS, Cunningham CK, Felton RP, et al. 2016. Differential effects of silver nanoparticles and silver ions on tissue accumulation, distribution, and toxicity in the Sprague–Dawley rat following daily oral gavage administration for 13-weeks. Toxicol Sci, published on line.
  • Braakhuis HM, Gosens I, Krystek P, Boere JA, Cassee FR, Fokkens PH, et al. 2014. Particle size dependent deposition and pulmonary inflammation after short-term inhalation of silver nanoparticles. Part Fibre Toxicol 11:49
  • Brown JS, Wilson WE, Grant LD. 2005. Dosimetric comparisons of particle deposition and retention in rats and humans. Inhal Toxicol 17:355–85.
  • Catsakis LH, Sulica VI. 1978. Allergy to silver amalgams. Oral Surg Oral Med Oral Pathol 46:371–5.
  • Cho EA, Lee WS, Kim KM, Kim SY. 2008. Occupational generalized argyria after exposure to aerosolized silver. J Dermatol 35:759–60.
  • Cho HS, Sung JH, Song KS, Kim JS, Ji JH, Lee JH, et al. 2013. Genotoxicity of silver nanoparticles in lung cells of Sprague Dawley rats after 12 weeks of inhalation exposure. Toxics 1:36–45.
  • Cho KH, Park JE, Osaka T, Park SG. 2005. The study of antimicrobial activity and preservative effects of nanosilver ingredient. Electrochim Acta 51:956–60.
  • Davis JA, Gift JS, Zao QJ. 2011. Introduction to benchmark dose methods and U.S. EPA's benchmark dose software (BMDS) version 2.1.1. Toxicol Appl Pharmacol 254:181–91.
  • de Winter-Sorkina R, Cassee FR. 2003. From concentration to dose: factors influencing airborne particulate matter deposition in humans and rats, Report No. 650010031. Bilthoven, The Netherlands: Netherlands National Institute for Public Health and the Environment (RIVM).
  • DFG (Deutsche Forschungsgemeinschaft). 2006. MAK- und BAT-Werte-Liste, Deutsche Forschungsgemeinschaft. Weinheim, Germany: Wiley-VCH,
  • ECHA (European Chemicals Agency). 2012. Occupational exposure estimation. In: Guidance on Information Requirements and Chemical Safety Assessment. Helsinki, Finland: European Chemicals Agency (Chapter R.14).
  • Faustman EM1, Allen BC, Kavlock RJ, Kimmel CA. 1994. Dose–response assessment for developmental toxicity. I. Characterization of database and determination of no observed adverse effect levels. Fundam Appl Toxicol 23:478–86.
  • Foldbjerg R, Dang DA, Autrup H. 2011. Cytotoxicity and genotoxicity of silver nanoparticles in the human lung cancer cell line, A549. Arch Toxicol 85:743–50.
  • Geiser M, Kreyling WG. 2010. Deposition and biokinetics of inhaled nanoparticles. Part Fibre Toxicol 7:2
  • Gregoratto D, Bailey MR, Marsh JW. 2010. Modelling particle retention in the alveolar–interstitial region of the human lungs. J Radiol Prot 30:491–512.
  • Hadrup N, Lam HR. 2014. Oral toxicity of silver ions, silver nanoparticles and colloidal silver – a review. Regul Toxicol Pharmacol 68:1–7.
  • Heyl T. 1979. Contact dermatitis from silver coat. Contact Dermatitis 5:197.
  • ICRP (International Commission on Radiologic Protection). 1994. Human respiratory tract model for radiological protection. Oxford, England: Pergamon, Elsevier Science Ltd., International Commission on Radiological Protection Publication No. 66.
  • ISO TS 80004-2. 2015. Nanotechnologies-Vocabulary – Part 2: Nano-objects. Geneva: ISO.
  • Jarabek AM, Asgharian B, Miller FJl. 2005. Dosimetric adjustments for interspecies extrapolation of inhaled poorly soluble particles (PSP). Inhal Toxicol 17:317–34.
  • Ji JH, Jung JH, Kim SS, Yoon JU, Park JD, Choi BS, et al. 2007. Twenty-eight-day inhalation toxicity study of silver nanoparticles in Sprague–Dawley rats. Inhal Toxicol 19:857–71.
  • Kavlock RJ, Allen BC, Faustman EM, Kimmel CA. 1995. Dose–response assessments for developmental toxicity. IV. Benchmark doses for fetal weight changes. Fundam Appl Toxicol 26:211–22.
  • Keller J, Wohlleben W, Ma-Hock L, Strauss V, Gröters S, Küttler K, et al. 2014. Time course of lung retention and toxicity of inhaled particles: short-term exposure to nano-Ceria. Arch Toxicol 88:2033–59.
  • Kim JS, Song KS, Sung JH, Ryu HR, Choi BG, Cho HS, et al. 2013. Genotoxicity, acute oral and dermal toxicity, eye and dermal irritation and corrosion and skin sensitisation evaluation of silver nanoparticles. Nanotoxicology 7:953–60.
  • Kim JS, Sung JH, Ji JH, Song KS, Lee JH, Kang CS, et al. 2011. In vivo genotoxicity of silver nanoparticles after 90-day silver nanoparticle inhalation exposure. Saf Health Work 2:34–8.
  • Kim YS, Kim JS, Cho HS, Rha DS, Kim JM, Park JD, et al. 2008. Twenty-eight-day oral toxicity, genotoxicity, and gender-related tissue distribution of silver nanoparticles in Sprague–Dawley rats. Inhalat Toxicol 20:575–83.
  • Kim YS, Song MY, Park JD, Song KS, Ryu HR, Chung YH, et al. 2010. Subchronic oral toxicity of silver nanoparticles. Part Fibre Toxicol 7:20.
  • Kimmel CA, Kavlock RJ, Allen BC, Faustman EM. 1995. The application of benchmark dose methodology to data from prenatal developmental toxicity studies. Toxicol Lett 82-83:549–54.
  • Landsiedel R, Fabian E, Ma-Hock L, van Ravenzwaay B, Wohlleben W, Wiench K, et al. 2012. Toxico-/biokinetics of nanomaterials. Arch Toxicol 86:1021–60.
  • Lankveld DP, Oomen AG, Krystek P, Neigh A, Troost – de Jong A, Noorlander CW, et al. 2010. The kinetics of the tissue distribution of silver nanoparticles of different sizes. Biomaterials 31:8350–61.
  • Lee JH, Ahn K, Kim SM, Jeon KS, Lee JS, Yu IJl. 2012b. Continuous 3-day exposure assessment of workplace manufacturing silver nanoparticles. J Nanopart Res 14:1134.
  • Lee JH, Kim YS, Song JS, Ryu HR, Sung JH, Park JD, et al. 2013a. Biopersistence of silver nanoparticles in tissues from Sprague–Dawley rats. Part Fibre Toxicol 10:36.
  • Lee JH, Kwon M, Ji JH, Kang CS, Ahn KH, Han JH, et al. 2011. Exposure assessment of workplaces manufacturing nanosized TiO2 and silver. Inhalat Toxicol 23:226–36.
  • Lee JH, Mun J, Park JD, Yu IJ. 2012a. A health surveillance case study on workers who manufacture silver nanomaterials. Nanotoxicology 6:667–9.
  • Lee JH, Sohn EK, Ahn JS, Ahn K, Kim KS, Lee JH, et al. 2013b. Exposure assessment of workers in printed electronics workplace. Inhalat Toxicol 25:426–34.
  • Leo BF, Chen S, Kyo Y, Herpoldt KL, Terrill NJ, Dunlop IE, et al. 2013. The stability of silver nanoparticles in a model of pulmonary surfactant. Environ Sci Technol 47:11232–40.
  • Li P, Li J, Wu C, Wu Q, Li J. 2005. Synergistic antibacterial effects of beta-lactam antibiotic combined with silver nanoparticles. Nanotechnology 16:1912–17.
  • Li X, Lenhart JJ, Walker HW. 2012. Aggregation kinetics and dissolution of coated silver nanoparticles. Langmuir 28:1095–1104.
  • Loeschner K, Hadrup N, Qvortrup K, Larsen A, Gao X, Vogel U, et al. 2011. Distribution of silver in rats following 28 days of repeated oral exposure to silver nanoparticles or silver acetate. Part Fibre Toxicol 8:18.
  • Ma R, Levard C, Marinakos SM, Cheng Y, Liu J, Michel FM, et al. 2012. Size-controlled dissolution of organic-coated silver nanoparticles. Environ Sci Technol 46:752–9.
  • Marks R. 1966. Contact dermatitis due to silver. Br J Dermatol 78:606–7.
  • Maronpot RR. 2014. Liver, Bile Duct – Hyperplasia. National Toxicology Program Nonneoplastic Lesion Atlas. Available at: http://ntp.niehs.nih.gov/nnl/hepatobiliary/liver/bdhyperp/index.htm. Accessed on 7 January 2015.
  • Miller FJ, Kimbell JS, Preston RJ, Overton JH, Gross EA, Conolly RB. 2011. The fractions of respiratory tract cells at risk in formaldehyde carcinogenesis. Inhalat Toxicol 23:689–706.
  • Morones JR, Elechiguerra JL, Camacho A, Holt K, Kouri JB, Ramírez JT, et al. 2005. The bactericidal effect of silver nanoparticles. Nanotechnology 16:2346–53.
  • NIOSH (National Institute for Occupational Safety and Health). 2013. Occupational Exposure to Carbon Nanotubes and Nanofibers. Current Intelligence Bulletin 65. Cincinnati, OH: NIOSH.
  • OECD (Organisation for Economic Co-operation and Development), 2010. Report of the Workshop on Risk Assessment of Manufactured Nanomaterials in a regulatory context. No. 21 – ENV/JM/MONO(2010)10. Paris: OECD.
  • OECD. 2014. Genotoxicity of Manufactured Nanomaterials: Report of the OECD Expert Meeting. ENV/JM/MONO(2014)34. Paris: OECD.
  • Oller AR, Oberdorster G. 2010. Incorporation of particle size differences between animal studies and human workplace aerosols for deriving exposure limit values. Regulat Toxicol Pharmacol 57:181–94.
  • Park EJ, Bae E, Yi J, Kim Y, Choi K, Lee SH, et al. 2010. Repeated-dose toxicity and inflammatory responses in mice by oral administration of silver nanoparticles. Environ Toxicol Pharmacol 30:162–8.
  • Park J, Kwak BK, Bae E, Lee J, Kim Y, Choi K, et al. 2009. Characterization of exposure to silver nanoparticles in a manufacturing facility. J Nanopart Res 11:1705–12.
  • Park K, Park EJ, Chun IK, Choi K, Lee SH, Yoon J, Lee BC. 2011. Bioavailability and toxicokinetics of citrate-coated silver nanoparticles in rats. Arch Pharm Res 34:153–8.
  • Pauluhn J. 2010. Multi-walled carbon nanotubes (Baytubes): approach for derivation of occupational exposure limit. Regul Toxicol Pharmacol 57:78–89.
  • Quadros ME, Marr LC. 2010. Environmental and human health risks of aerosolized silver nanoparticles. J Air Waste Manag Assoc 60:770–81.
  • SCENIHR. 2014. Nanosilver: safety, health and environmental effects and role in antimicrobial resistance. Scientific Committee on Emerging and Newly Identified Health Risks. Available at: http://ec.europa.eu/health/scientific_committees/consultations/public_consultations/scenihr_consultation_17_en.htm. Accessed on 7 January 2015.
  • Schäfer B, Brocke JV, Epp A, Götz M, Herzberg F, Kneuer C, et al. 2013. State of the art in human risk assessment of silver compounds in consumer products: a conference report on silver and nanosilver held at the BfR in 2012. Arch Toxicol 87:2249–62.
  • Slob W. 2002. Dose–response modeling of continuous endpoints. Toxicol Sci 66:298–312.
  • Snipes MB. 1989. Long-term retention and clearance of particles inhaled by mammalian species. Crit Rev Toxicol 20:175–211.
  • Sondi I, Salopek-Sondi B. 2004. Silver nanoparticles as antimicrobial agent: a case study on E. coli as a model for Gram-negative bacteria. J Colloid Interface Sci 275:177–82.
  • Song KS, Sung JH, Ji JH, Lee JH, Lee JS, Ryu HR, et al. 2013. Recovery from silver-nanoparticle-exposure-induced lung inflammation and lung function changes in Sprague Dawley rats. Nanotoxicology 7:169–80.
  • Stebounova LV, Adamcakova-Dodd A, Kim JS, Park H, O'Shaughnessy PT, Grassian VH, et al. 2011. Nanosilver induces minimal lung toxicity or inflammation in a subacute murine inhalation model. Part Fibre Toxicol 8:5
  • Sung JH, Ji JH, Park JD, Yoon JU, Kim DS, Jeon KS, et al. 2009. Subchronic inhalation toxicity of silver nanoparticles. Toxicol Sci 108:452–61.
  • Sung JH, Ji JH, Song KS, Lee JH, Choi KH, Lee SH, et al. 2011. Acute inhalation toxicity of silver nanoparticles. Toxicol Ind Health 27:149–54.
  • Sung JH, Ji JH, Yoon JU, Kim DS, Song MY, Jeong J, et al. 2008. Lung function changes in Sprague-Dawley rats after prolonged inhalation exposure to silver nanoparticles. Inhal Toxicol 20:567–74.
  • SUVA, 2007. Grenzwerte am Arbeitsplatz, Schweizerische Unfallversicherungsanstalt. Luzern, Germany
  • US EPA. 1994. Methods for Derivation of Inhalation Reference Concentrations and Application of Inhalation Dosimetry, Research Triangle Park, NC: USEPA.
  • US EPA. 2012. Benchmark Dose Technical Guidance. Washington, DC, United States Environmental Protection Agency. Research Triangle Park, NC, USEPA
  • USEPA. 2015. Benchmark Dose Software Version 2.6.0. Available at: http://www2.epa.gov/bmds.
  • Utembe W, Potgieter K, Stefaniak AB, Gulumian M. 2015. Dissolution and biodurability: important parameters needed for risk assessment of nanomaterials. Part Fibre Toxicol 12:11
  • van der Zande M, Vandebriel RJ, Van Der Zande M, Vandebriel RJ, Van Doren E, Kramer E, Herrera Rivera Z, Serrano-Rojero CS, et al. 2012. “Distribution, elimination, and toxicity of silver nanoparticles and silver ions in rats after 28-day oral exposure”. ACS Nano 6:7427–42.
  • Walczak AP, Fokkink R, Peters R, Tromp P, Herrera Rivera ZE, Rietjens IM, et al. 2013. Behaviour of silver nanoparticles and silver ions in an in vitro human gastrointestinal digestion model. Nanotoxicology 7:1198–210.
  • Wignall JA, Shapiro AJ, Wright FA, Woodruff TJ, Chiu WA, Guyton KZ, et al. 2014. Standardizing benchmark dose calculations to improve science-based decisions in human health assessments. Environ Health Perspect 122:499–505.
  • Woodrow Wilson International Center for Scholars, W. 2015. The project on emerging nanotechnologies. Available at: http://www.nanotechproject.org/inventories/.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.